131 results about "Mesenchyma" patented technology

The present disclosure relates to cellular compositions that are modified to introduce a nucleic acid or vector expressing the same. Such compositions may be used to deliver nucleic acid to a target cell and treat disease such as cancer.

Provided herein are methods and related compositions for enhancing or enhanced partial reprogramming of target cells in a subject in need thereof (e.g., a human subject suffering from or at risk of a disease), the method comprising administering a plurality of mesenchymal lineage progenitor or stem cells (MLPSCs), exosomes derived therefrom, or conditioned culture media derived therefrom to a subject that expresses or will express one or more reprogramming factors in a population of target cells, whereby a plurality of the target cells in the subject become partially reprogrammed, but not fully reprogrammed.

The present invention relates to CD73 + CD44 + , CD90 + A method for generating a population of mesenchymal stromal cells (MSCs) is provided. + CD44 + , CD90 + MSCs are used in methods to generate terminally differentiated osteogenic, adipogenic, and chondrogenic cells from pluripotent stem cells (PSCs), which involve the use of a single agent, a WNT signaling pathway activator (e.g., a GSK3β inhibitor), in adherent cultures of PSCs.

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.

The invention relates to the technical field of biomedicine detection, and discloses a tumor cell marker detection system for predicting the activation state of intracellular protein kinase. Comprising a marker detection module used for qualitatively detecting epithelial cell markers, mesenchymal cell markers, cell polarity markers and extracellular matrix related markers in tumor cells; the data processing module is used for performing cross validation on an epithelial cell marker, a mesenchymal cell marker, a cell polarity marker and an extracellular matrix related marker; the dynamic weighting module is used for performing dynamic weighting on different markers based on a complex system theory, and endowing epithelial cadherin with a higher weight; and the judgment module is used for determining whether epithelial intercellular substance transformation occurs or not according to the dynamically weighted marker data, and predicting the activation state of intracellular phosphoinositide 3-kinase alpha and the invasiveness of tumor cells based on the determination result of the epithelial intercellular substance transformation.

The invention discloses a method for inducing fibroblasts to be reprogrammed into mesenchymal matrix-like cells (MLCs) by using small chemical molecules and application of the mesenchymal matrix-like cells (MLCs) in the anti-aging field. The invention discloses a set of specific chemical small molecule composition and an induction scheme thereof, which can be used for efficiently reprogramming fibroblasts from somatic cells into MLCs. Furthermore, the huge potential of the MLCs obtained by the method in anti-aging research is deeply explored, and the effect of the MLCs is proved to be obviously superior to that of umbilical cord mesenchymal stem cells in the aspects of reversing cell aging phenotypes and recovering tissue functions. The invention not only provides a new stem cell source strategy for avoiding the ethical and safety problems of the traditional reprogramming technology, but also lays a solid cell foundation for developing a novel, safe and effective anti-aging therapy based on cell transplantation or secreted factors.

The present application provides bispecific antibodies comprising a first antigen-binding fragment directed against human mesenchymal-epithelial transformation factor (c-Met) and a second antigen-binding fragment directed against human epidermal growth factor receptor (EGFR). In addition, the invention also provides medical and biological uses of the bispecific antibody.

The invention relates to the technical field of cell preparation, and particularly discloses a cell drug and a preparation method thereof.The cell drug comprises mesenchymal cells and pharmaceutically acceptable auxiliary materials; the mesenchymal cell is characterized in that the expression of SOX2, DPPA4 and MYCN genes is negative; the auxiliary material comprises a sodium chloride solution containing albumin; the concentration of the sodium chloride solution is 0.1%-2%; the content of the albumin in the sodium chloride solution is 0.1%-10%. The cell medicine is simple in composition and good in auxiliary material compatibility, the motility of active ingredients can be protected, and the safety and reliability of the cell medicine are remarkably improved by optimizing the preparation process.

The invention provides a nucleic acid molecule, a mesenchymal stromal cell for promoting angiogenesis and application thereof, and relates to the technical field of biomedicine, the nucleic acid molecule encodes an HGF protein, or encodes a VEGF165 protein and an HGF protein; the first signal peptide is used as a signal peptide of VEGF165 protein, and the second signal peptide is used as a signal peptide of HGF protein. Through a gene modification strategy, the MSC cell containing the nucleic acid molecule stably and efficiently expresses VEGF165 and / or HGF, and the expression quantity of the VEGF165 and / or HGF is obviously higher than that of the MSC without the nucleic acid molecule. The capability of promoting endothelial cell migration is realized; meanwhile, the cells can also remarkably promote proliferation and tube formation of HUVEC cells, and the strong angiogenesis promoting effect of the cells is further proved. The technical problem that in the prior art, nucleic acid molecules for expressing VEGF165 or / HGF cannot be stably and efficiently expressed is solved.

The present invention provides chimeric antigen receptors (CARs) comprising an extracellular domain which specifically binds to Mesenchymal Epithelial Transition factor (MET); a transmembrane (TM) domain; a co-stimulatory signaling domain; and, a primary intracellular signaling domain. The application further relates to polynucleotides and recombinant vectors encoding the CARs, as well as to host cells and methods for producing host cells that express the CARs. The application further relates to pharmaceutical compositions comprising the CAR modified cells. Methods for stimulating elimination of a MET-expressing cell and for treating a MET-positive cancer using the CAR modified cells in a subject are also disclosed.

This invention relates to a method for expanding immune cells, the method comprising co-culturing the immune cells and at least one epithelial organoid, wherein the epithelial organoid comprises more epithelial cells than mesenchymal cells. Also provided are immune cells obtainable by the method, an in vitro population of innate lymphoid cells (ILCs) comprising at least 5×103 ILCs, pharmaceutical compositions and uses thereof.

This cell-based formulation contains SSEA-3-positive pluripotent stem cells derived from mesenchymal tissue of a living body or derived from cultured mesenchymal cells. This cell-based formulation is characterized in that the formulation is for administration to address diseases and / or post-acute sequelae caused by SARS-CoV-2 infection. The present invention makes it possible to provide a cell-based formulation that contains pluripotent stem cells and is used for treating and / or preventing SARS-CoV-2 infection-caused diseases such as pneumonia and pulmonary fibrosis and SARS-CoV-2 infection-caused post-acute sequelae such as olfactory dysfunctions.

The invention relates to the application of inhibition of transcription factor 4 (TCF4 / ITF2) in the treatment of cancer. This in particular in combination therapy in conjunction with an immunotherapeutic compound (such as for treating cancers poorly responding or refractive to immunotherapy). In particular, inhibition of TCF4 / ITF2 is capable of restoring response to immunotherapy such as immune checkpoint inhibitor therapy. Expression levels of TCF4 / ITF2 as well as levels of mesenchymal-like cancer cells in a cancer lesion are predictive of future response to immunotherapy early after initiation of the immunotherapy. Further part of the invention are methods of detecting mesenchymal-like cancer cells.

The present invention relates to the discovery that different stem cell types (e.g., bone marrow-derived mesenchymal stem cells (RM-MSC) and adipose-derived mesenchymal stem cells (AT-MSC)) undergo large changes in lung epithelial marker 5 expression depending on the substrate on which they are cultured. The present invention includes methods and compositions for differentiating of mesenchymal stem cells, such as bone marrow and adipose tissue mesenchymal stem cells, into lung cells, populations of lung cells, and methods of alleviating or treating a lung defect in a subject in need thereof.

A method of increasing the chondrogenic potential mediated by TGFβ of a mesenchymal stromal cell (MSC) or a population of mesenchymal stromal cells (MSCs), comprising the step of increasing the amount of TGFβR1, and / or decreasing the amount of TGFβR2, and / or decreasing the amount of and / or ACVRL1 of the MSC or a population of mesenchymal stromal cells (MSCs).

The purpose of the present invention is to provide a new medical use of pluripotent stem cells (Muse cells) in regenerative therapy. The present invention provides a cell preparation and a pharmaceutical composition for treating, preventing, alleviating and / or delaying onset of spinal cord infarction, comprising SSEA-3-positive pluripotent stem cells isolated from biologically derived mesenchymal tissues or cultured mesenchymal cells. The present invention is based on a mechanism in which Muse cells are administered to a subject having spinal cord infarction, and the cells are grafted to the tissue of the spinal cord infarction site, thereby treating spinal cord infarction.

An implantable membrane construct including a maximum pore size (MPS) less than 2 microns and opposing sides, each side of the construct having a surface roughness (Sa) greater than about 0.5 microns is disclosed. When the luminal surface of the implantable membrane construct has a surface roughness (Sa) greater than about 0.5 microns, mesenchymal cells do not form at the interface of the lumen and the first layer (i.e., luminal interface) such that the mesenchymal cells do not impede the flow of oxygen and nutrients to the graft cells (when implanted). When implanted, the outermost layer of the implantable membrane construct enables cellular penetration, vascularization, and anchoring of the construct. The implantable membrane construct includes single layer embodiments and multiple layer embodiments. Encapsulation devices utilizing the implantable membrane constructs to encapsulate biological entities (e.g., cells) into a patient are also provided.

The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Described herein are hydrogel compositions comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, hydroxypropyl methyl cellulose and a plurality of mesenchymal stromal cells.Additionally described herein are compositions for treatment, and methods for treatment of a disease, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, hydroxypropyl methyl cellulose and a plurality of mesenchymal stromal cells.

The invention belongs to the technical field of medical apparatus and instruments, and discloses an ECMO and mesenchymal cell filter combined extracorporeal membrane oxygenation device, which comprises: a cart for transferring the extracorporeal membrane oxygenation device; the gas mixer is arranged below the cart; the blood pump is arranged above the cart; through the linkage design of the three filtering layers and a layer-by-layer pressure relief mechanism, dynamic self-adaptive switching of a filtering path in a blocked state is achieved, when the pressure of a certain filtering layer rises due to blood cell blockage, the corresponding pressure relief valve is automatically opened, blood is guided to be shunted to the next filtering layer, overload rupture or blood flow interruption of a single filtering layer is avoided, and the safety of a patient is improved. The layered pressure release and filtering relay mechanism can significantly prolong the continuous operation time of the device, reduce the clinical membrane replacement frequency, and reduce the mechanical stress of a single assembly, prolong the service life of the filtering layer and reduce the operation risk through the layer-by-layer dispersion of the pressure load.

The present invention provides, as a technique that can be used for obtaining a skin organoid or a skin tissue structure that skillfully mimics the structure and function of the skin of a living body from stem cells, a skin organoid comprising cells that are derived from pluripotent stem cells and have the ability to differentiate into cells constituting the skin, the skin organoid having a lumen, the skin organoid having an epidermal cell layer comprising cells having the ability to differentiate into epidermis on the surface facing the lumen, and the skin organoid having a mesenchymal cell layer, on the outside of the epidermal cell layer, comprising cells having the ability to differentiate into dermis or subcutaneous tissue. The epidermal cell layer is configured by laminating, in this order from the lumen side, a granular layer comprising cells that express loricrin, a spinous layer comprising cells that express KRT10, and a basal layer comprising cells that express KRT5 and p63, and has hair pegs invaginating the mesenchymal cell layer.

The present disclosure relates generally to compositions and methods for treating cancer. More specifically, the present disclosure relates to compositions and their use in one of altering the transformation of epithelial cells to mesenchymal cells or the transformation of mesenchymal cells to epithelial cells of tumor cells. The method comprises administering to the subject a composition comprising a PI3K inhibitor, such as paxalisib (GDC-0084), and an immunotherapy that is not targeted to cancer stem cells (CSC), wherein the immunotherapy is an immune checkpoint antagonist or a PARP inhibitor.

The present invention provides a method for producing regenerated hair follicle primordium that allows production of regenerated hair follicle primordium more easily and in larger amounts compared to conventional production methods.A method for producing regenerated hair follicle primordium comprising a step of obtaining hair follicle primordium by culturing a first population of cells comprising epithelial cells and a second population of cells comprising mesenchymal cells while allowing them to be in contact is provided. The production method of the present invention is characterized in that at least either one of said first population of cells and said second population of cells has formed cell aggregates before said contact, and a culture support is not used when contacting the other population of cells with said cell aggregate.

The present invention discloses a bioactive scaffold for slowly releasing Apt19S to recruit endogenous stem cells and guide the straight regeneration of central nervous system axons and its application. The bioactive scaffold is composed of acellular optic nerve (DON) and aptamer Apt19S, and its preparation method comprises the following steps: 1. preparing a DON scaffold. 2. activating the carboxyl group on the surface of the DON scaffold. 3. The DON scaffold is combined with amino-modified Apt19S through an amidation reaction to obtain the DON‑Apt19S scaffold (abbreviated as DON‑A). This bioactive scaffold can continuously release Apt19S, recruit ALPL-positive endogenous neural stem cells and mesenchymal cells, guide the straight regeneration of central nervous system axons, and provide a microenvironment for neurogenesis and angiogenesis for in situ spinal cord repair. The bioactive scaffold has important transformation prospects and application value in the repair of central nervous system injuries.

The present application relates to the preparation and use of an anilino pyridine alkynyl compound in treating fibrotic diseases. Specifically, the compound of the present application has the structure of Formula I, wherein the definitions of each group and substituent are described in the specification. The present application also provides that the compound significantly improves the inhibitory effect of COL1A1 in the fibrotic epithelial-mesenchymal transition (EMT) model, and the compound has lower hepatotoxicity, and is expected to be used for preparing a drug for preventing and / or treating fibrotic diseases.

This document relates to methods and materials for using engineered mesenchymal stromal cells (MSCs) to treat mammals (e.g., humans) in need of immunosuppression (e.g., humans at risk of having or having one or more autoimmune diseases (e.g., graft versus host disease (GVHD))). For example, provided are CAR-MSCs (e.g., MSCs expressing chimeric antigen receptors (CARs) having (e.g., engineered to have) elevated levels of one or more immunosuppressive polypeptides, elevated levels of one or more regenerative polypeptides, and / or elevated levels of one or more transport polypeptides) (e.g., MSCs expressing chimeric antigen receptors (CARs) having the ability to bind to tissue-specific antigens). Also provided are methods of administering one or more CAR-MSCs provided herein to a mammal (e.g., a human) in need of immunosuppression (e.g., a human at risk of having or having one or more autoimmune diseases such as GVHD) to treat the mammal.

The invention provides a method of producing a population of CD73+ CD44+, CD90+ mesenchymal stromal cells (MSCs). The CD73+ CD44+, CD90+ MSCs are used in methods of generating terminally differentiated osteogenic, adipogenic and chondrogenic cells from pluripotent stem cells (PSCs). The differentiation method includes the use of a single agent, WNT signaling pathway activator such as a GSK3β inhibitor, used on adherent culture of PSCs.

The invention relates to the field of dermatology and cosmetology and can be used for regenerating wounds and preventing and correcting age-related skin changes, as well as for stimulating hair growth. The proposed composition contains as active ingredient the secretome of mesenchymal stromal cells (MSCs) derived from mammalian adipose tissue, the secretome being provided in an amount of 50-70 ‎μg / ml and being characterized by the presence of the following secretion products: FGF-2, KGF, TGF-β, PDGF, TGF-α, IGF-1, EGF, HGF, VEGF, G-CSF, GM-CSF, PGE2, ANG-1, ANG-2, MCP-1, MMPs, cysteine, tyrosine, arginine, glycine, histidine, isoleucine, lysine hydrochloride, methionine, phenylalanine, serine, threonine, tryptophan and valine. Also proposed is a method for producing the claimed composition, which includes techniques and conditions for harvesting and cultivating MSCs, making it possible to obtain a secretome having constituents effective for the treatment and regeneration of skin and hair.

This invention discloses the application of the CEMIP-ITGA5 axis as a target in the preparation of products that regulate epithelial-mesenchymal transition (EMT) and metastasis in lung adenocarcinoma, belonging to the fields of tumor molecular biology and precision medicine. Through TCGA-LUAD cohort bioinformatics analysis, immunohistochemical verification of clinical specimens, cell function experiments, and a nude mouse subcutaneous xenograft model, this invention discovers and confirms that the CEMIP-ITGA5 axis participates in regulating epithelial-mesenchymal transition, migration, invasion, and metastasis-related malignant progression in lung adenocarcinoma. Specifically, CEMIP positively regulates ITGA5 expression, thereby promoting EMT, proliferation, migration, invasion, and in vivo tumorigenesis in lung adenocarcinoma cells. Based on this, the present invention provides two applications: Firstly, by detecting the expression levels of the dual genes CEMIP and ITGA5, a kit for assessing the risk of epithelial-mesenchymal transition (EMT) and metastasis in lung adenocarcinoma can be prepared. The combined detection of CEMIP and ITGA5 can reflect the activation status of the CEMIP-ITGA5 axis at both the upstream regulatory molecule and downstream effector molecule levels, providing auxiliary molecular evidence for assessing EMT and metastasis-related risks in lung adenocarcinoma. Secondly, by targeting and inhibiting the expression or function of CEMIP and / or ITGA5, drugs can be prepared to inhibit epithelial-mesenchymal transition, migration, invasion, and metastasis-related malignant progression in lung adenocarcinoma, effectively reversing the epithelial-mesenchymal transition phenotype and inhibiting tumor malignant progression. This invention provides novel molecular targets and technical solutions independent of known signaling pathways for prognostic assessment and targeted therapy of lung adenocarcinoma.